The US approval of Newron Pharmaceuticals SPA’s add-on Parkinson’s disease therapy, Xadago (safinamide), announced March 21, may have been welcomed by that company’s investors, but after nearly a decade with few if any new products, the therapeutic niche is rapidly becoming more competitive, with several new products nearing the market.
Parkinson’s Niche To Expand With New Drugs, More Patients
Newron’s new Parkinson’s disease therapy, Xadago, approved in the US after a regulatory delay, is expected to be the first of several new products to be introduced in this long-neglected therapeutic sector.